Premium
Postresection recurrence of hepatocellular carcinoma treated by arterial embolization: Analysis of prognostic factors
Author(s) -
Takayasu Kenichi,
Wakao Fumihiko,
Moriyama Noriyuki,
Muramatsu Yukio,
Yamazaki Susumu,
Kosuge Tomoo,
Takayama Tadatoshi,
Okada Shuichi,
Okazaki Nobuo,
Makuuchi Masatoshi
Publication year - 1992
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840160409
Subject(s) - medicine , hepatocellular carcinoma , arterial embolization , embolization , hepatology , angiography , radiology , carcinoma , gastroenterology , surgery
Of 270 consecutive patients with hepatocellular carcinoma who underwent surgery, 50 who had recurrence and were subsequently treated with transcatheter arterial embolization were analyzed. The longest interval between surgery and recurrence in the 50 patients who underwent transcatheter arterial embolization was 7 yr. Recurrence was initially found in the remnant liver in all patients but one; extrahepatic metastases were detected in 13 patients (26%) during follow‐up. A “multiple” type was the most common (64%) hepatic recurrence pattern on angiography, followed by the “solitary” (16%) and “tumor thrombus” (12%) patterns. Hepatic recurrence was most frequently found in the ipsilateral lobe (48%) relative to the site of the primary hepatocellular carcinoma. Multivariate analysis of the factors affecting survival after transcatheter arterial embolization indicated that recurrence pattern (p = 0.025) and distant metastases (p = 0.011) were significant. Of 13 patients with distant metastases, 11 had the “multiple” pattern of hepatic recurrence. Survival rates for all 50 patients after initial surgery and after transcatheter arterial embolization were 90% and 64%, respectively, at 1 yr; 52% and 24%, respectively, at 3 yr; and 27% and 5%, respectively, at 5 yr. On analysis of survival rates after transcatheter arterial embolization in 37 patients with recurrence only in the liver and of the response of recurrent hepatocellular carcinoma to transcatheter arterial embolization, a significant difference was noted between those with “partial response” and “progressive disease” (p < 0.05) and between those with “no change” and “progressive disease” (p < 0.05). (HEPATOLOGY 1992;16:906–911.)